X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.8 10.9 235.9% View Chart
P/BV x 4.0 1.9 214.5% View Chart
Dividend Yield % 0.3 0.9 34.5%  

Financials

 GLENMARK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-18
GLENMARK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9933,083 32.2%   
Low Rs7291,902 38.3%   
Sales per share (Unadj.) Rs325.5589.7 55.2%  
Earnings per share (Unadj.) Rs39.3284.0 13.8%  
Cash flow per share (Unadj.) Rs48.7310.5 15.7%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.21.0 23.2%  
Book value per share (Unadj.) Rs159.21,467.0 10.9%  
Shares outstanding (eoy) m282.17180.27 156.5%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.64.2 62.6%   
Avg P/E ratio x21.98.8 249.7%  
P/CF ratio (eoy) x17.78.0 220.5%  
Price / Book Value ratio x5.41.7 318.3%  
Dividend payout %5.18.8 57.8%   
Avg Mkt Cap Rs m242,991449,332 54.1%   
No. of employees `00013.06.8 189.5%   
Total wages/salary Rs m16,40819,881 82.5%   
Avg. sales/employee Rs Th7,083.915,535.6 45.6%   
Avg. wages/employee Rs Th1,265.42,905.4 43.6%   
Avg. net profit/employee Rs Th855.17,482.5 11.4%   
INCOME DATA
Net Sales Rs m91,857106,310 86.4%  
Other income Rs m3742,595 14.4%   
Total revenues Rs m92,230108,906 84.7%   
Gross profit Rs m20,36751,599 39.5%  
Depreciation Rs m2,6444,773 55.4%   
Interest Rs m2,37329,783 8.0%   
Profit before tax Rs m15,72419,638 80.1%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827-28,764 -13.3%   
Profit after tax Rs m11,08851,203 21.7%  
Gross profit margin %22.248.5 45.7%  
Effective tax rate %24.3-146.5 -16.6%   
Net profit margin %12.148.2 25.1%  
BALANCE SHEET DATA
Current assets Rs m68,746118,154 58.2%   
Current liabilities Rs m27,027462,260 5.8%   
Net working cap to sales %45.4-323.7 -14.0%  
Current ratio x2.50.3 995.2%  
Inventory Days Days8527 319.8%  
Debtors Days Days9647 205.3%  
Net fixed assets Rs m24,132113,727 21.2%   
Share capital Rs m282361 78.3%   
"Free" reserves Rs m44,643264,093 16.9%   
Net worth Rs m44,925264,454 17.0%   
Long term debt Rs m45,363242,206 18.7%   
Total assets Rs m117,639726,834 16.2%  
Interest coverage x7.61.7 459.5%   
Debt to equity ratio x1.00.9 110.3%  
Sales to assets ratio x0.80.1 533.9%   
Return on assets %11.411.1 102.7%  
Return on equity %24.719.4 127.5%  
Return on capital %19.110.3 185.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15215,110 371.6%   
Fx outflow Rs m8,0844,298 188.1%   
Net fx Rs m48,06810,813 444.6%   
CASH FLOW
From Operations Rs m6,574-159,666 -4.1%  
From Investments Rs m-7,124-17,677 40.3%  
From Financial Activity Rs m5,432186,503 2.9%  
Net Cashflow Rs m1,9929,364 21.3%  

Share Holding

Indian Promoters % 48.3 52.9 91.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.0 172.5%  
FIIs % 34.4 26.6 129.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   56,727 93,274 60.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - VENUS REMEDIES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS